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SEROLOGICAL EVIDENCE OF Rickettsia parkeri AS THE ETIOLOGICAL AGENT 
OF RICKETTSIOSIS IN URUGUAY
Ismael A. CONTI-DÍAZ(1), Jonas MORAES-FILHO(2), Richard C. PACHECO(2) & Marcelo B. LABRUNA(2)
SUMMARY
We report three new rickettsiosis human cases in Uruguay. The three clinical cases presented clinical manifestations similar to 
previous reported cases of Rickettsia parkeri in the United States; that is mild fever (< 40 oC), malaise, headache, rash, inoculation 
eschar at the tick bite site, regional lymphadenopathy, and no lethality. Serological antibody-absorption tests with purified antigens of 
R. parkeri and Rickettsia rickettsii, associated with immunofluorescence assay indicated that the patients in two cases were infected by 
R. parkeri. Epidemiological and clinical evidences, coupled with our serological analysis, suggest that R. parkeri is the etiological agent 
of human cases of spotted fever in Uruguay, a disease that has been recognized in that country as cutaneous-ganglionar rickettsiosis.
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INTRODUCTION
Human rickettsiosis caused by Rickettsia parkeri, a spotted fever 
group agent, was first reported in the United States in 2004, 65 years 
after the first isolation of the agent from Amblyomma maculatum 
ticks in that same country12. Nowadays, R. parkeri is considered an 
emerging agent in the United Sates, with increasing reported cases 
since its official recognition as a human pathogen13. In addition, it is 
likely that a significant number of previously reported cases of Rocky 
Mountain spotted fever, presumably caused by Rickettsia rickettsii, 
were in fact caused by R. parkeri13,14. Besides the United States, R. 
parkeri has been reported in Amblyomma triste ticks from Argentina, 
Brazil, and Uruguay9,15,16. In this last country, a number of cases of 
rickettsiosis, often referred as cutaneous-ganglionar rickettsiosis, have 
been reported since 1990, characterized by a small papulo-nodular lesion 
at the tick attachment site, an influenza-like illness (fever, headache, 
malaise), and regional lymphadenopathy in all observed cases; some 
cases also presented generalized rash. No further clinical complication 
was observed3,4,5. Ticks associated with these cases were initially 
misidentified as A. maculatum and the rickettsial agent was prematurely 
identified as R. conorii. Subsequently, the tick species associated with 
rickettsiosis in Uruguay was confirmed to be A. triste (the closely related 
species A. maculatum is not present in Uruguay), whereas clinical and 
epidemiological observations have strongly indicated that the etiological 
agent could be R. parkeri, yet to be confirmed in the laboratory10,11,16. 
Herein, we report three new rickettsiosis cases in Uruguay, two of them 
with serological evidence that they were caused by R. parkeri after 
antibody absorption tests.
CASE REPORTS
Case 1: A 6-year-old male child was admitted at the hospital on 07 
September 2006 with fever and a cervical lymphadenopathy. One week 
before, he was in contact with ticks after a visit to the Hermoza Beach 
area, Piriápolis, southern Uruguay. In the hospital, two ticks found 
attached to his scalp were collected and identified as adult females of A. 
triste. Eschars were observed at the sites of tick bites on the scalp. Oral 
clindamycin was prescribed, but one week later generalized rash appeared 
on his trunk, arms, legs, and face. Large cervical lymphadenopathy was 
observed. Erythromycin was prescribed and no clinical abnormalities 
were observed in the following week. Patient’s blood serum collected two 
weeks after onset of fever was tested for rickettsiosis through IFA for R. 
parkeri, R. rickettsii, R. felis, R. amblyommii, R. rhipicephali, and R. bellii 
antigens, as previously described7,8. Serum end-point titers to these six 
antigens were 2,048, 1,024, 64, 256, 512, and < 64, respectively. A second 
serum sample collected 30 days later was tested solely to R. parkeri, 
and R. rickettsii, giving the endpoint titers 2,048 and 512, respectively. 
Serum cross-absorption tests were performed in order to indicate the 
most possible rickettsial antigen responsible for inducing infection in the 
human patient. For this purpose, aliquots of the first serum sample were 
absorbed with either R. parkeri or R. rickettsii crude antigens. Production 
of crude rickettsial antigens was performed following a previously 
described protocol1, which consisted in purifying rickettsia from infected 
Vero cells suspended in Minimum Essential Medium (MEM) by passage 
through a 25-gauge syringe needle six times to lyse the cells, sequential 
passage of the lysate through 5- and 2-µm syringe filters to remove 
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cellular debris, and centrifugation of the filtrates at 18,400 g at 4 oC for 
20 min to pellet rickettsiae. Rickettsiae were resuspended in SFG buffer 
and protein concentration was determined using the bicinchoninic acid 
protein assay (Pierce, Rockford, IL, USA) on rickettsiae dissolved in 100 
mM of Tris, pH 7.4, and 2% sodium dodecyl sulfate. After centrifugation 
of 0.250 mL of purified rickettsiae, a pellet containing approximately 
1.5 mg of antigen was resuspended in 1 mL of the test serum at a 1:64 
dilution. The serum-antigen suspension was incubated at 37 °C for four 
hours followed by incubation at room temperature for 20 hours on a 
rocker. Thereafter, the suspension was centrifuged at 13,000 × g for 15 
minutes, saving the supernatant that was the absorbed serum. Each of the 
absorbed sera was then tested by IFA to either R. parkeri or R. rickettsii 
crude antigens. If serum absorbed with one Rickettsia species showed 
no or minimal reaction against both antigens, and a strong reaction to 
only one of the two antigens when absorbed with the second Rickettsia 
species, this serum was considered to contain antibodies stimulated by 
the Rickettsia species (or a very closely related species) that elicited the 
strong reaction in the second cross-absorption and had absorbed all the 
antibodies in the first reaction6. After absorption with R. rickettsii, the 
serum demonstrated a 1,024 titer against R. parkeri and no antibodies 
against R. rickettsii, but after absorption with R. parkeri, there was no 
reaction against either of the two Rickettsia antigens. The anti-Rickettsia 
antibodies in this patient was considered to have been stimulated possibly 
by R. parkeri. 
Case 2: In May 2007, a 57-year-old man from a rural area of 
Maldonado County, southern Uruguay, presented with fever and malaise. 
No tick bites were recorded within the previous few weeks. While living 
in the same rural area stated above, the patient had a history of recurrent 
fever, malaise, and tick bites during the previous two years, including an 
inguinal lymphadenopathy associated with fever in 2005. Patient’s blood 
serum collected on May 2007 was tested by IFA, showing end-point 
titers of 2,048, 2,048, 64, 512, 128, and 256, for R. parkeri, R. rickettsii, 
R. felis, R. amblyommii, R. rhipicephali, and R. bellii, respectively. A 
second serum sample collected in July 2007, when patient presented no 
clinical abnormality, showed endpoint titers of 2,048, 1,024, 64, 256, 
256, and 128 for R. parkeri, R. rickettsii, R. felis, R. amblyommii, R. 
rhipicephali, and R. bellii, respectively. Aliquots of the first serum sample 
were absorbed with R. parkeri and R. rickettsii antigens, as described 
above. After absorption with R. rickettsii, the serum demonstrated a 1,024 
titer against R. parkeri, and 256 against R. rickettsii, but after absorption 
with R. parkeri, there was no reaction against either of the two Rickettsia 
antigens. The anti-Rickettsia antibodies in this patient were considered 
to have been stimulated possibly by R. parkeri.
Case 3: At 6 November 2005, a 38-year-old man from a rural area of 
Canelones County, Uruguay, presented with a cutaneous lesion on dorsum 
of the left foot secondary to tick bite suffered two weeks before. The 
lesion at the tick bite site was a small vesicula, which promptly became 
ulcerated and crusted, surrounded by a burnt reddish area, accompanied 
by fever (37-38.5 ºC), painful regional lymphadenopathy, dorso-lumbar 
pain, and headache. Four days later, a black lesion (6-7 mm in diameter) 
of necrotic character was noted on the dorsum of left foot, encircled 
by a macular rounded area of 7-8 cm in diameter, reddish-violaceous 
in color, without local warm, constituted by multiple small petechial 
lesions (Fig.1). Edema of the foot and inflammatory lymphadenopathy 
at the inguino-crural zone of the same leg was also observed. On the 
antero-posterior areas of the trunk scarce and asymptomatic rose-colored 
macular lesions, 1 cm in diameter (rash) were present. Lyme disease was 
first diagnosed and oral amoxicillin at 1 g per day was indicated by a 
7-day period, with improvement in general symptoms. Patient’s blood 
serum collected two weeks after onset of symptoms was tested by IFA, 
showing end-point titers of 4,096 to either R. parkeri or R. rickettsii, and 
512 to R. felis. No serum cross-absorption tests were done in this case. 
Other laboratory findings: red blood cells sedimentation rate: 35 mm 
at the first hour; red blood cells count: 4,610,000 per mm3; hematocrit: 
39.3%; leucocyte cells count: 7,230 per mm3; platelets: 220,000 per mm3, 
urine examination: normal; bacteriological examination of foot cutaneous 
lesion in blood agar medium: negative. 
DISCUSSION
The three clinical cases of rickettsiosis reported in the present 
study presented clinical manifestations similar to previous reported 
cases due to R. parkeri in the United States; that is mild fever (<40 oC), 
malaise, headache, rash, inoculation eschar at the tick bite site, regional 
lymphadenopathy, and no lethality12,18. The three cases also presented 
similar pattern in the serological reactivities to different rickettsial 
antigens, characterized by higher and similar titers to R. parkeri and 
R. rickettsii, and substantially lower titers to other rickettsial antigens, 
including the spotted fever group agents R. felis, R. amblyommii, and R. 
rhipicephali. Similarly, human cases of R. parkeri infection in the United 
States showed similar IFA titers to R. parkeri and R. rickettsii13. The 
three patients of the present study showed clinical improvement without 
been treated with specific antibiotics (tetracyclines or chloramphenicol) 
that are usually recommended to treat rickettsiosis2. This condition is in 
accordance with previous reported cases of acute rickettsiosis due to R. 
parkeri in the United States, characterized by clinical manifestations that 
resolved even in the absence or delay treatment with specific antibiotics13. 
Since no tissue sample from the patients was available in proper 
conditions to be tested by a direct diagnosis of rickettsia, we performed 
cross-absorption tests to try to indirectly identify the rickettsial agent 
responsible for the antibody response. In two cases, results clearly 
suggested that the patients were infected by R. parkeri. The three cases 
recalled previous tick infestations, but taxonomic identification of the 
tick was possible only in case 1, as A. triste. Since all three cases are from 
southern Uruguay, where A. triste is far the most common (or the only 
one reported) human-biting tick17, it is quite possible that the other two 
cases were also related to A. triste infestations. Interestingly, only the adult 
Fig. 1 - A cutaneous lesion (inoculation eschar) on dorsum of the left foot of a patient (case 
3 in the text) presenting clinical cutaneous-ganglionar rickettsiosis.
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stage of A. triste bites humans, and the seasonal activity of adult A. triste 
(August to February) coincides with seasonal increases in cases of human 
spotted fever reported in Uruguay17. All these epidemiological and clinical 
evidences, coupled with our serological analysis, indicate that R. parkeri is 
the possible etiological agent of human cases of spotted fever in Uruguay, 
a disease that has been recognized in that country as cutaneous-ganglionar 
rickettsiosis. We are aware that we can not assume with certainty that the 
illness observed on the three patients were due to an acute infection by 
R. parkeri because we did not show seroconversion between acute and 
convalescent sera, a crucial condition for proper serological diagnosis of 
acute rickettsiosis2. This information is particularly important in case 2, 
where patient history is more compatible with an acute rickettsial infection 
that might have occurred previous to the moment when serum was collected 
for analysis. Nonetheless, we present for the first time serological evidence 
of R. parkeri human infection in Uruguay. Finally, further studies with 
isolation and molecular identification of R. parkeri from Uruguayan 
patients will definitely confirm our findings. Since R. parkeri-infected 
A. triste ticks are also present in Argentina and Brazil, the disease will 
probably be diagnosed in these countries during the next years. 
RESUMO
Evidência sorológica de Rickettsia parkeri como agente etiológico 
de rickettsiose no Uruguai
São relatados três novos casos humanos de rickettsiose no Uruguai. 
Os três casos clínicos apresentam manifestações clínicas semelhantes 
às descritas em casos de infecção por Rickettsia parkeri previamente 
relatados nos Estados Unidos, tais como: febre moderada (< 40 oC), 
mal-estar, cefaléia, exantema, escara de inoculação no sítio de fixação 
do carrapato, linfadenopatia regional e ausência de letalidade. Testes 
sorológicos de absorção de anticorpos com antígenos de R. parkeri e 
Rickettsia rickettsii, associados à reação de imunofluorescência indireta, 
sugerem que os pacientes de dois casos foram infectados por R. parkeri. 
Evidências clínicas e epidemiológicas, associadas com nossas análises 
sorológicas, sugerem que R. parkeri é o agente etiológico de casos 
humanos de febre maculosa no Uruguai, uma doença que tem sido 
reconhecida naquele país como rickettsiose cutâneo-ganglionar.
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